CINECA IRIS Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi di Torino.
AperTO è l'archivio istituzionale Open Access destinato a raccogliere, rendere visibile e conservare la produzione scientifica dell'Università degli Studi di Torino.
EnglishSummary This study evaluates the effect of alendronate on osteoclastogenesis, cytokine production, and bone resorp- tion in postmenopausal women. We suggest that it acts on mature bone resorbing osteoclasts after 3 months of treatment, whereas, after 1 year, it diminishes their formation by reducing their precursors and serum RANKL. Introduction Osteoclasts are the target cells of bisphosph- onates, though the most drug-sensitive steps of their formation and activity have not been determined. The present study evaluates the effect of alendronate on osteoclastogenesis, cytokine production, and bone resorp- tion in postmenopausal women. Methods The study was conducted on 35 osteoporotic women; 15 were pretreated with alendronate 70 mg/week, whereas, 20 were treated with calcium 1 g/day and vitamin D 800 IU/day. After 3 months, 30 received alendonate 70/mg, vitamin D 2800 IU/week, and calcium 1 g/day for 12 months (combined therapy), whereas, the other five patients remained on calcium 1 g/day and vitamin D 800 IU/day. The following parameters were assessed before and after therapy: changes in bone resorption markers, circulating osteoclast precursors, formation of osteoclasts in peripheral blood mononuclear cell cultures, their viability, and variations in cytokines production. Results After 3 months of alendronate, there was no significant reduction in the number of osteoclast precursors, osteoclast formation and viability, and cytokine levels, whereas, there was a significant reduction of bone resorption markers. One year of the combined therapy, on the other hand, reduced osteoclast precursors, osteoclast formation, and serum RANKL, whereas, calcium plus vitamin D alone had no effect. Conclusions We suggest that alendronate mainly acts on mature bone resorbing osteoclasts in the short term, whereas, its long-term administration diminishes their formation by reducing their precursors and serum RANKL.
| Titolo: | Alendronate reduces osteoclast precursors in osteoporosis |
| Autori Riconosciuti: | |
| Autori: | P D’Amelio; A Grimaldi; MA Cristofaro; M Ravazzoli; PA Molinatti; GP Pescarmona; G Isaia |
| Data di pubblicazione: | 2010 |
| Abstract: | Summary This study evaluates the effect of alendronate on osteoclastogenesis, cytokine production, and bone resorp- tion in postmenopausal women. We suggest that it acts on mature bone resorbing osteoclasts after 3 months of treatment, whereas, after 1 year, it diminishes their formation by reducing their precursors and serum RANKL. Introduction Osteoclasts are the target cells of bisphosph- onates, though the most drug-sensitive steps of their formation and activity have not been determined. The present study evaluates the effect of alendronate on osteoclastogenesis, cytokine production, and bone resorp- tion in postmenopausal women. Methods The study was conducted on 35 osteoporotic women; 15 were pretreated with alendronate 70 mg/week, whereas, 20 were treated with calcium 1 g/day and vitamin D 800 IU/day. After 3 months, 30 received alendonate 70/mg, vitamin D 2800 IU/week, and calcium 1 g/day for 12 months (combined therapy), whereas, the other five patients remained on calcium 1 g/day and vitamin D 800 IU/day. The following parameters were assessed before and after therapy: changes in bone resorption markers, circulating osteoclast precursors, formation of osteoclasts in peripheral blood mononuclear cell cultures, their viability, and variations in cytokines production. Results After 3 months of alendronate, there was no significant reduction in the number of osteoclast precursors, osteoclast formation and viability, and cytokine levels, whereas, there was a significant reduction of bone resorption markers. One year of the combined therapy, on the other hand, reduced osteoclast precursors, osteoclast formation, and serum RANKL, whereas, calcium plus vitamin D alone had no effect. Conclusions We suggest that alendronate mainly acts on mature bone resorbing osteoclasts in the short term, whereas, its long-term administration diminishes their formation by reducing their precursors and serum RANKL. |
| Volume: | 21(10) |
| Pagina iniziale: | 1741 |
| Pagina finale: | 1750 |
| Digital Object Identifier (DOI): | 10.1007/s00198-009-1129-1 |
| URL: | http://www.springerlink.com/content/454n457407454265/ |
| Parole Chiave: | Alendronate; Osteoclast; Osteoclast precursors; Osteoporosis; RANKL |
| Rivista: | OSTEOPOROSIS INTERNATIONAL |
| Appare nelle tipologie: | 03A-Articolo su Rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| Alendronate reduces osteoclast precursors in osteoporosis.pdf | 1 Ver. finale autore | Accesso riservato | Utenti riconosciuti Richiedi una copia | |
| Alendronate reduces osteoclast precursors in osteoporosis.pdf | 1 Ver. finale autore | Open Access Visualizza/Apri |
Copyright © 2019